Scott Isaacs
@scottisaacsmd
Followers
17K
Following
4K
Media
2K
Statuses
6K
President @theaace, endocrinologist, obesity medicine, #MASLD, Emory Med School adjunct faculty. Posts are my own.
Atlanta, GA
Joined November 2010
JAMA Internal Medicine patient information on GLP-1 medications.
0
4
28
A new long-acting PYY3-36 analogue (PYY1875) was tested for weight loss, both alone and alongside semaglutide, in animal models and clinical trials. Combined treatment led to modest extra weight loss, but benefits weren’t clinically meaningful and higher doses caused more side
0
4
18
Excellent review article on the brain control of energy homeostasis and implications for anti-obesity pharmacotherapy. New peptide-based drugs directly target brain pathways to deliver safe, sustained weight loss. The CNS and gut-brain axis are key to next-gen obesity treatments
3
29
88
Honored to contribute to this @EverydayHealth article on an important milestone: the FDA has approved Wegovy for adults with MASH & significant liver fibrosis. This new indication expands treatment options for patients facing serious liver disease.
everydayhealth.com
The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as MASH and severe fibrosis.
1
2
13
The approval of #semaglutide for #MASH reinforces the urgent need to expand screening initiatives and implement coordinated, multidisciplinary care models to ensure that more patients are identified early and have access to newly approved therapies and comprehensive disease
3
14
64
New brain-targeting anti-obesity peptides (GLP-1, GIP, and dual agonists) access brain sites, such as the area postrema and arcuate nucleus, where they engage neurons controlling appetite, energy use, and reward response. By tapping into these circuits, they help suppress hunger
6
91
288
State of the art review about the benefits and risks of testosterone treatment in middle-aged and older men with moderate degrees of hypogonadism.
4
42
203
Breaking! The FDA has approved Wegovy #semaglutide to treat #MASH in adults with moderate-to-advanced fibrosis.
6
116
337
Algorithm for diagnosis of steatotic liver disease from the Diabetes Canada Clinical Practice Guidelines for MASLD.
3
37
105
The brain’s appetite circuits can rewire themselves. AgRP neurons remodel to control hunger, weight & glucose levels. Obesogenic environments cause maladaptive changes that fuel overeating & obesity. Healthy states lead to adaptive plasticity that restores energy balance.
1
13
47
The symptoms of thyroid disease and menopause can overlap, making diagnosis a challenge.
1
2
11
Screening for steatotic liver disease can face biases:.Length-time bias → slow-progressing cases overrepresented, fast-progressing cases missed. Lead-time bias → earlier detection may only appear to extend survival without changing outcomes.
0
27
65
Steatotic liver disease often goes undetected until it becomes severe, raising the risk of cirrhosis and liver cancer. This new review in @TheLancet highlights the need for accurate tests, cost-effective interventions, and strategies that ensure equity while minimizing harm.
6
65
200
Honored to be included in this photo with the board of the Ohio River Region Society of Endocrinology (ORRSE) representing @TheAACE. Grateful for the opportunity to listen and engage with such an inspiring group!
2
1
9
It was great to meet our new @theaace Fellow-in-Training, @nataliafret, at the Ohio River Region Society of Endocrinology Annual Meeting in French Lick, Indiana.
0
1
7
Attending the Ohio River Region Society of Endocrinology #ORRSE2025 in French Lick, Indiana for a listening session to explore collaboration opportunities with @TheAACE.
0
1
4
